SOUDERTON, Pennsylvania, February 28, 2011 /PRNewswire/ -- Packaging, storage and distribution of schedule I-V controlled substances is now a fully functional capability of Almac's new North American Headquarters in Souderton, PA. As the phased transition nears its end, the portfolio of services and capacity offered to customers continues to grow as a result of the $120 million investment.

Storage of controlled materials is located in a highly secured temperature monitored cage and vault. Both locations meet DEA (Drug Enforcement Administration) requirements in addition to providing substantially greater capacity. The total 3,980 square feet of storage space comes as a response to demand expressed by both the industry and existing clients. This, as well as expansive growth in areas of storage for ambient, refrigerated and frozen products, is part of Almac's ongoing mission to ensure drugs get to market faster.

Dave Setley, Head of Business Development, commented on the addition by saying: "The expanded storage and distribution of controlled drug product from the NAHQ further solidifies Almac's position as a leader in the clinical supply arena."

Almac's facility growth has also allowed the Company to offer a broad range of pharmaceutical development services from the US headquarters site - all under one roof, mirroring the successful mix of services offered by the Global Headquarters in Northern Ireland. Clients can now carry out their trial supply services from the Souderton (PA) location, as well as IWR/IVRS and analytical services if needed. This proves to be an unparalleled advantage in the market and sets Almac aside from its competitors in the industry.

As the phased transition nears its end, Almac is busily working around the clock to make sure current projects continue without interruption. Almac invites existing and prospective clients, as well as the media, to schedule tours of the facility or learn more by visiting: http://www.almacgroup.com.

About Almac Group

The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.

The company employs over 3,000 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Almac has now moved into its new $120m North American Headquarters located in Souderton PA.

For more information about the Almac Group, please visit http://www.almacgroup.com or e-mail [email protected]

http://www.defacto.com

SOURCE Almac